JP2010507576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010507576A5 JP2010507576A5 JP2009533406A JP2009533406A JP2010507576A5 JP 2010507576 A5 JP2010507576 A5 JP 2010507576A5 JP 2009533406 A JP2009533406 A JP 2009533406A JP 2009533406 A JP2009533406 A JP 2009533406A JP 2010507576 A5 JP2010507576 A5 JP 2010507576A5
- Authority
- JP
- Japan
- Prior art keywords
- deuterium
- compound
- compound according
- pharmaceutical composition
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 229910052805 deuterium Inorganic materials 0.000 claims 11
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 241000191967 Staphylococcus aureus Species 0.000 claims 3
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- 241000606860 Pasteurella Species 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 241000193996 Streptococcus pyogenes Species 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 230000037006 agalactosis Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229960003644 aztreonam Drugs 0.000 claims 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims 1
- 229960001139 cefazolin Drugs 0.000 claims 1
- 229960000484 ceftazidime Drugs 0.000 claims 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- -1 deuterium compound Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 229960001699 ofloxacin Drugs 0.000 claims 1
- 229960002292 piperacillin Drugs 0.000 claims 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940037649 staphylococcus haemolyticus Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85389006P | 2006-10-23 | 2006-10-23 | |
| US60/853,890 | 2006-10-23 | ||
| US97463707P | 2007-09-24 | 2007-09-24 | |
| US60/974,637 | 2007-09-24 | ||
| PCT/US2007/022516 WO2008127300A2 (en) | 2006-10-23 | 2007-10-23 | Oxazolidinone derivatives and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010507576A JP2010507576A (ja) | 2010-03-11 |
| JP2010507576A5 true JP2010507576A5 (https=) | 2010-12-09 |
| JP5302200B2 JP5302200B2 (ja) | 2013-10-02 |
Family
ID=39864509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009533406A Expired - Fee Related JP5302200B2 (ja) | 2006-10-23 | 2007-10-23 | オキサゾリジノン誘導体および使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080139563A1 (https=) |
| EP (1) | EP2099299A4 (https=) |
| JP (1) | JP5302200B2 (https=) |
| CA (1) | CA2703011A1 (https=) |
| WO (1) | WO2008127300A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8796267B2 (en) * | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| WO2008070619A1 (en) * | 2006-12-04 | 2008-06-12 | Auspex Pharmaceuticals, Inc. | Deuterated oxazolidinones and their use as antibiotics |
| US20090062283A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched linezolid |
| WO2009154754A2 (en) * | 2008-06-17 | 2009-12-23 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| SG10201406571YA (en) * | 2009-10-13 | 2014-11-27 | Melinta Therapeutics Inc | Pharmaceutical compositions |
| CN104327004A (zh) * | 2014-11-17 | 2015-02-04 | 重庆华邦制药有限公司 | 高纯度利奈唑胺氮氧化物的制备方法 |
| EP3351553A4 (en) | 2015-09-17 | 2019-06-19 | Seoul National University R & DB Foundation | BROKEN OR FOLDED HELIXFUL PEPTIDE OR PEPTIDE ANALOG WITH ANTIMICROBIAL ACTIVITY AGAINST GRAM NEGATIVE BACTERIA AND USE THEREOF |
| WO2017089892A1 (en) * | 2015-11-25 | 2017-06-01 | Astrazeneca Ab | Deuterated isoxazole derivatives and their use as metabotropic glutamate receptor potentiators |
| US11608320B2 (en) | 2020-02-02 | 2023-03-21 | Kuwait University | Oxazolidinone hydroxamic acid derivatives |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| PT1019385E (pt) * | 1995-09-15 | 2004-06-30 | Upjohn Co | N-oxidos de aminoaril-oxazolidinona |
| US6255304B1 (en) * | 1997-05-30 | 2001-07-03 | Pharmacia & Upjohn Company | Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
| US6884429B2 (en) * | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
| KR20010015910A (ko) * | 1998-01-23 | 2001-02-26 | 로렌스 티. 마이젠헬더 | 옥사졸리디논 조합 라이브러리, 조성물 및 제조 방법 |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| PT1104760E (pt) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
| AR027261A1 (es) * | 2000-02-02 | 2003-03-19 | Upjohn Co | Linezolid forma cristalina ii |
| US20030060465A1 (en) * | 2000-12-19 | 2003-03-27 | Jilani Jamal A. | Prodrugs of non-steroidal anti-inflammatory and carboxylic acid containing compounds |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| AU2006274037B2 (en) * | 2005-07-26 | 2012-04-26 | Takeda Gmbh | Isotopically substituted pantoprazole |
| CA2616383C (en) * | 2005-07-29 | 2015-06-09 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| CN101309917B (zh) * | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| WO2008030382A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| US8796267B2 (en) * | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| WO2008070619A1 (en) * | 2006-12-04 | 2008-06-12 | Auspex Pharmaceuticals, Inc. | Deuterated oxazolidinones and their use as antibiotics |
-
2007
- 2007-10-23 JP JP2009533406A patent/JP5302200B2/ja not_active Expired - Fee Related
- 2007-10-23 US US11/877,666 patent/US20080139563A1/en not_active Abandoned
- 2007-10-23 EP EP07873459A patent/EP2099299A4/en not_active Withdrawn
- 2007-10-23 CA CA2703011A patent/CA2703011A1/en not_active Abandoned
- 2007-10-23 WO PCT/US2007/022516 patent/WO2008127300A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010507576A5 (https=) | ||
| JP2009503024A5 (https=) | ||
| JP2018513215A5 (https=) | ||
| JP2018534348A5 (https=) | ||
| RU2018114480A (ru) | Соли и твердые формы монобактамного антибиотика | |
| JP2009502743A5 (https=) | ||
| JP2014530866A5 (https=) | ||
| DE60331056D1 (de) | 6-11 bicyclische ketolidderivate | |
| JP2012508734A5 (https=) | ||
| JP2011530534A5 (https=) | ||
| JP2018534288A5 (https=) | ||
| JP2015521617A5 (https=) | ||
| JP2015528468A5 (https=) | ||
| JP2009503025A5 (https=) | ||
| RU2013137752A (ru) | Твердые формы ингибитора гиразы (r)-1-этил-3-[6-фтор-5[2-(1-гидрокси-1-метил-этил) пиримидин-5-ил]-7-(тетрагидрофуран-2-ил)-1н-бензимидазол-2-ил] мочевины | |
| CN115315423A (zh) | 取代芳基类化合物 | |
| CN108368079A (zh) | 治疗细菌感染的化合物及方法 | |
| JP2020536966A5 (https=) | ||
| MX2010002932A (es) | Macrolidos de biarilo con puente en 6, 11. | |
| NZ593058A (en) | (r)-3-(e)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy) pyridine, its salts, its synthesis and its use as ligand for nicotinic acetylcholinergic receptors | |
| WO2006063039A3 (en) | 3, 6-bicyclolides | |
| Soler et al. | Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic bronchitis | |
| JP6077725B1 (ja) | 呼吸器感染症治療剤 | |
| JP2008546824A5 (https=) | ||
| JP2010511669A5 (https=) |